Peptide hormones on Notably News

Peptide hormones

Follow Peptide hormones on Notably News to receive short updates to your email — rarely!

We include updates on Semaglutide, Tirzepatide, Insulin, Growth hormone, Human chorionic gonadotropin, Liraglutide, Prolactin, Thyroid-stimulating hormone, Luteinizing hormone, Glucagon, Parathyroid hormone, Insulin-like growth factor 1, Leptin, Follicle-stimulating hormone, Ghrelin, Insulin glargine ... and more.

February 2025	Insulin aspart Insulin aspart-szjj (Merilog and Merilog Solostar), the first biosimilar to Novolog, was approved for medical use in the United States by the FDA. Sanofi-Aventis received the approval.
May 18 2024	Luis Moroder Luis Moroder passed away, concluding a distinguished career in peptide chemistry and biological research.
March 2023	Insulin lispro Lilly announced a program capping their insulin prices at $35 per month to improve affordability for patients with chronic conditions.
2022	Insulin glargine Insulin glargine became the 28th most commonly prescribed medication in the United States, with over 18 million prescriptions issued.
2022	Insulin lispro Insulin lispro became the 70th most commonly prescribed medication in the United States, with over 9 million prescriptions, demonstrating its widespread clinical adoption for diabetes management.
2022	Insulin aspart Insulin aspart became the 76th most commonly prescribed medication in the United States, with over 8 million prescriptions, highlighting its widespread medical adoption.
April 2022	Insulin aspart Truvelog Mix 30 was approved for medical use in the European Union.
February 2022	Insulin aspart The CHMP adopted a positive opinion for Truvelog Mix 30, a medicinal product for diabetes treatment by sanofi-aventis groupe.
October 2021	Insulin aspart Kirsty was approved for medical use in Canada.
July 2021	Insulin glargine Insulin glargine-yfgn (Semglee) was approved by the FDA as the first interchangeable biosimilar of Lantus, with approval granted to Mylan Pharmaceuticals.
July 2021	Insulin glargine The US Food and Drug Administration (FDA) approved Semglee (insulin glargine-yfgn), an interchangeable biosimilar insulin product for diabetes treatment.
July 2021	Insulin analog Insulin glargine-yfgn (Semglee) was approved for medical use in the United States.
February 2021	Insulin aspart Kixelle was approved for medical use in the European Union and renamed to Kirsty.
2020	Luis Moroder Honored with the Ernesto Scoffone Award by the Italian Peptide Society, further cementing his reputation in the field of peptide research.
2020	NPH insulin NPH insulin (insulin isophane) became the 221st most commonly prescribed medication in the United States, with over 2 million prescriptions.
2020	NPH insulin The combination of human insulin with insulin isophane became the 246th most commonly prescribed medication in the United States, with over 1 million prescriptions.
2020	Insulin analog The 2007 Cochrane Collaboration meta-analysis was updated, reaffirming the previous findings about insulin analog effectiveness and safety.
December 2020	Insulin aspart The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency adopted a positive opinion for Kixelle, a medicinal product for diabetes treatment by Mylan IRE Healthcare Limited.
October 2020	Insulin aspart Trurapi was approved for medical use in Canada.
October 2020	Insulin aspart Truvelog and Truvelog Solostar were approved for medical use in Australia.
June 2020	Insulin lispro Insulin lispro (Lyumjev) was approved for use in the United States.
March 2020	Insulin lispro Insulin lispro (Lyumjev) was approved for use in the European Union.
January 2020	Insulin lispro The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended granting of a marketing authorization for insulin lispro acid (brand name Lyumjev) for the treatment of diabetes in adults.
April 2019	Insulin lispro Eli Lilly and Company announced the production of a lower-cost insulin version priced at $137.35 per vial, aimed at addressing high out-of-pocket costs for patients.
2018	Luis Moroder Received the Akabori Memorial Lecture Award from the Japanese Peptide Society, recognizing his international impact in peptide science.
March 2018	Insulin glargine Insulin glargine (Semglee) was approved for medical use in the European Union.
March 2018	Insulin analog Insulin glargine-yfgn (Semglee) received approval for medical use in the European Union.
December 2017	Insulin lispro Insulin lispro injection (brand name Admelog) was approved for use in the United States.
July 2017	Insulin lispro Insulin lispro Sanofi was granted marketing authorization as a biosimilar in the European Union.
January 2017	Insulin glargine Lusduna was approved for medical use in the European Union.
2015	Insulin glargine Toujeo, a three-fold more concentrated formulation of insulin glargine, was introduced after receiving FDA approval.
2015	Insulin glargine Eli Lilly's insulin glargine became available in most countries under the brand names Basaglar (in the US) and Abasaglar (in the EU).
2015	Insulin lispro Humalog insulin vial price increased to $234 or $29.36 per 100 units in the United States.
2014	Insulin glargine Patent protection for insulin glargine expired in Europe and the United States, opening the way for competitor products.
2014	Insulin glargine The patent for insulin glargine expired in most jurisdictions, potentially allowing for more affordable generic versions of the medication.
September 2014	Insulin glargine Abasaglar was approved for medical use in the European Union, marking a significant milestone for insulin glargine biosimilars.
2013	Insulin analog Novo Nordisk's Tresiba 'insulin degludec' analog is approved in Europe by the European Medicines Agency (EMA), with additional monitoring.
2012	Growth hormone Dragos Roman from the FDA commented in a Vanity Fair article about the discrepancy between HGH prescriptions and actual HGH-deficiency patients, highlighting the complex regulatory landscape of HGH usage.
2011	Luis Moroder Granted an honorary doctorate (Doctor honoris causa) from the University of Cergy-Pontoise in Paris, acknowledging his academic and research achievements.

This contents of the box above is based on material from the Wikipedia articles NPH insulin, Luis Moroder, Insulin analog, Insulin aspart, Growth hormone, Insulin lispro & Insulin glargine, which are released under the Creative Commons Attribution-ShareAlike 4.0 International License.